Search Result

Results for "

reversible activator

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (2) Apoptosis (8) Autophagy (1) Btk (1) Cathepsin (2) Chloride Channel (2) Cholinesterase (ChE) (5) Deubiquitinase (1) DNA Methyltransferase (3) DOCK (1) Drug Metabolite (1) Endogenous Metabolite (5) Ephrin Receptor (4) Epigenetic Reader Domain (1) Epoxide Hydrolase (1) ERK (3) Factor Xa (1) Glucocorticoid Receptor (4) Histone Acetyltransferase (1) Histone Demethylase (1) Insecticide (3) Interleukin Related (5) Isotope-Labeled Compounds (1) JAK (3) Keap1-Nrf2 (5) Ligands for Target Protein for PROTAC (1) MMP (3) Monoamine Oxidase (1) NAMPT (1) NOD-like Receptor (NLR) (4) P2Y Receptor (3) Phosphatase (2) Phosphodiesterase (PDE) (5) Phospholipase (2) PKA (1) PKG (1) Potassium Channel (3) PPAR (2) Protease Activated Receptor (PAR) (5) Proteasome (2) Proton Pump (2) Reactive Oxygen Species (ROS) (3) Reference Standards (4) Sodium Channel (2) STAT (1) Thrombin (1) TNF Receptor (1) TRP Channel (3) Wnt (4) β-catenin (4)
By Research Areas:	Cancer (26) Cardiovascular Disease (12) Endocrinology (4) Infection (3) Inflammation/Immunology (22) Metabolic Disease (12) Neurological Disease (18)

By Targets:

AMPK (2)

Apoptosis (8)

Autophagy (1)

Btk (1)

Cathepsin (2)

Chloride Channel (2)

Cholinesterase (ChE) (5)

Deubiquitinase (1)

DNA Methyltransferase (3)

DOCK (1)

Drug Metabolite (1)

Endogenous Metabolite (5)

Ephrin Receptor (4)

Epigenetic Reader Domain (1)

Epoxide Hydrolase (1)

ERK (3)

Factor Xa (1)

Glucocorticoid Receptor (4)

Histone Acetyltransferase (1)

Histone Demethylase (1)

Insecticide (3)

Interleukin Related (5)

Isotope-Labeled Compounds (1)

JAK (3)

Keap1-Nrf2 (5)

Ligands for Target Protein for PROTAC (1)

MMP (3)

Monoamine Oxidase (1)

NAMPT (1)

NOD-like Receptor (NLR) (4)

P2Y Receptor (3)

Phosphatase (2)

Phosphodiesterase (PDE) (5)

Phospholipase (2)

PKA (1)

PKG (1)

Potassium Channel (3)

PPAR (2)

Protease Activated Receptor (PAR) (5)

Proteasome (2)

Proton Pump (2)

Reactive Oxygen Species (ROS) (3)

Reference Standards (4)

Sodium Channel (2)

STAT (1)

Thrombin (1)

TNF Receptor (1)

TRP Channel (3)

Wnt (4)

β-catenin (4)

By Research Areas:

Cancer (26)

Cardiovascular Disease (12)

Endocrinology (4)

Infection (3)

Inflammation/Immunology (22)

Metabolic Disease (12)

Neurological Disease (18)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112472

S3969	Sodium Channel	Metabolic Disease
S3969 is a potent and reversible activator of the human epithelial sodium channel (hENaC). The apparent EC₅₀ for S3969 activation of hENaC is 1.2 μm .

HY-113221

Isovalerylcarnitine	Proteasome Endogenous Metabolite	Metabolic Disease
Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis .

HY-N0826

Corynoline 5 Publications Verification	Cholinesterase (ChE) Keap1-Nrf2	Neurological Disease Inflammation/Immunology Cancer
Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC₅₀ of 30.6 μM . Corynoline exhibits anti-inflammatory activity by activating Nrf2 .

HY-144813

Gü2602	Cathepsin	Inflammation/Immunology Cancer
Gü2602 is a potent, reversible cathepsin K (CatK) inhibitor with a K_i of 0.013 nM for mature CatK (mCatK). Gü2602 suppresses the autocatalytic activation of the cathepsin K zymogen .

HY-12809

Optovin 1 Publications Verification	TRP Channel	Neurological Disease
Optovin is a reversible photoactivated TRPA1 ligand that enables light-mediated neuronal excitation. Optovin activates TRPA1 via structure-dependent photochemical reactions with redox-sensitive cysteine residues .

HY-109079A

Abeprazan hydrochloride DWP14012 hydrochloride; Fexuprazan hydrochloride	Proton Pump	Metabolic Disease
Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-107301

Dehydrosoyasaponin I Soyasaponin Be; DHS-I	Potassium Channel	Neurological Disease
Dehydrosoyasaponin I (Soyasaponin Be;DHS-I), a triterpene glycoside, is a potent and reversible *calcium-activated* potassium (maxi-K) channels** activator .

HY-144812

Gü1303	Cathepsin	Inflammation/Immunology Cancer
Gü1303 is a potent, reversible, slow-binding cathepsin K (CatK) inhibitor with a K_i of 0.91 nM for mature CatK (mCatK). Gü1303 suppresses the autocatalytic activation of the cathepsin K zymogen .

HY-163445

NAMPT activator-6	NAMPT	Cancer
NAMPT activator-6 is a NAMPT activator, a regulatory molecule for the optical control system of NAMPT and NAD+. NAMPT activator-6 can be used to design efficient photoswitchable proteolysis-targeting chimeras (PS-PROTACs) to achieve up-down reversible regulation of NAMPT and NAD+ in a light-dependent manner and reduce the toxicity associated with inhibitor-based PS-PROTACs. PS-PROTAC can be used to achieve antitumor activity, NAMPT, and NAD+ modulation in vivo via optical manipulation .

HY-113221R

Isovalerylcarnitine (Standard)	Reference Standards Proteasome Endogenous Metabolite	Metabolic Disease
Isovalerylcarnitine (Standard) is the analytical standard of Isovalerylcarnitine. This product is intended for research and analytical applications. Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis .

HY-170485

Thrombin inhibitor 13	Thrombin	Cardiovascular Disease
Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for thrombin (FIIa) with an IC₅₀ of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities .

HY-N0826R

Corynoline (Standard)	Reference Standards Cholinesterase (ChE) Keap1-Nrf2	Neurological Disease Inflammation/Immunology Cancer
Corynoline (Standard) is the analytical standard of Corynoline. This product is intended for research and analytical applications. Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC₅₀ of 30.6 μM . Corynoline exhibits anti-inflammatory activity by activating Nrf2 .

HY-109079

Abeprazan DWP14012; Fexuprazan	Proton Pump	Metabolic Disease
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H ⁺, K ⁺- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .

HY-136358

LDN-211904	Ephrin Receptor	Cancer
LDN-211904 is a potent and reversible EphB3 inhibitor with an IC₅₀ of 79 nM. LDN-211904 shows good metabolic stability in mouse liver microsomes. LDN-211904 with cetuximab could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab (HY-P9905) resistance in CRC .

HY-13030

(+)-JQ-1 Maximum Cited Publications 250 Publications Verification JQ1	Epigenetic Reader Domain Autophagy Ligands for Target Protein for PROTAC	Cancer
(+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC₅₀s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)) . (+)-JQ-1 also activates autophagy .

HY-18200

Atopaxar E5555; ER-172594-00	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor *protease-activated* receptor-1 (PAR-1)** antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease .

HY-107460

LDN-211904 oxalate	Ephrin Receptor	Cancer
LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC₅₀ of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC .

HY-W134005

Mg(Ⅱ)-EDTA disodium tetrahydrate Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate	Phosphatase	Others
Mg(Ⅱ)-EDTA disodium tetrahydrate is a reversible non-covalent activator of fructose diphosphatase (K_m=0.9 μM). Mg(Ⅱ)-EDTA disodium tetrahydrate synergistically activates fructose diphosphatase with free Mg ²⁺, promotes the hydrolysis of fructose-1,6-bisphosphate at pH≤8, and plays a role in enhancing the activity of key enzymes in gluconeogenesis .

HY-19837

BMS-986120	Protease Activated Receptor (PAR)	Inflammation/Immunology
BMS-986120 is a first-in-class oral and reversible protease-activated receptor 4 (PAR4) antagonist, with IC₅₀s of 9.5 nM and 2.1 nM in human and monkey blood, respectively. BMS-986120 has potent and selective antiplatelet effects .

HY-139664

GSK-3685032 5+ Cited Publications	DNA Methyltransferase	Cancer
GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC₅₀ of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .

HY-18200B

Atopaxar hydrobromide E5555 hydrobromide; ER 172594-06	Protease Activated Receptor (PAR) JAK Apoptosis	Cardiovascular Disease Cancer
Atopaxar (E5555) hydrobromide is a potent, orally active, selective and reversible thrombin receptor *protease-activated* receptor-1 (PAR-1)** antagonist. Atopaxar hydrobromide, an antiplatelet agent, interferes with platelet signaling. Atopaxar hydrobromide can be used for the research of atherothrombotic disease .

HY-19638A

Cangrelor tetrasodium 2 Publications Verification AR-C69931MX tetrasodium	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-147049

PAL-4	Epoxide Hydrolase	Metabolic Disease
PAL-4 (compound 4) is a potent, selective and reversible Lysophospholipase-like 1 (LYPLAL1) activator with EC₅₀ value of 0.39 μM and 0.49 μM for mice LYPLAL1 and huamn LYPLAL1, respectively. PAL-4 can be used for researching metabolic disorders .

HY-162333

BAL-0028	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC₅₀ value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with K_D values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .

HY-128358

MR-L2	Phosphodiesterase (PDE)	Neurological Disease
MR-L2 is a reversible and noncompetitive allosteric activator of long-isoform phosphodiesterase-4 (PDE4), activates representative PDE4 long-isoform variants (PDE4A4, PDE4B1, PDE4C3, PDE4D5). MR-L2 suppresses PGE2-induced MDCK cell cyst formation with an EC₅₀ of 1.2 μM .

HY-115537

NAE-IN-M22	Apoptosis	Cancer
NAE-IN-M22 is a potent, selective and reversible inhibitor of *NEDD8 activating* enzyme (NAE)**, with potency in micromolar range. NAE-IN-M22 inhibits multiple cancer cell lines and induces apoptosis in A549 cells. NAE-IN-M22 also can inhibit tumor growth in vivo .

HY-19638

Cangrelor AR-C69931MX	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist .

HY-E70028

UDP-sugar pyrophosphorylase (BlUSP)	Endogenous Metabolite	Metabolic Disease
UDP-sugar pyrophosphorylase (BlUSP) is the enzyme capable of activating glucose-1-phosphate (Glc-1-P) to UDP-glucose (UDP-Glc). UDP-sugar pyrophosphorylase (BlUSP) catalyzes a reversible transfer of the uridyl group from UTP to sugar-1-phosphate, producing UDP-sugar and pyrophosphate (PPi) .

HY-118628

(E/Z)-BML264 5+ Cited Publications N-(p-Amylcinnamoyl) anthranilic acid; ACA	Phospholipase TRP Channel	Cardiovascular Disease
(E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A₂ (PLA₂) inhibitor and TRP channel blocker . (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of *calcium-activated* chloride channels**, has potential to treat arrhythmia .

HY-161125

(+)-JQ1-OH	Drug Metabolite	Others
(+)-JQ1-OH is the major metabolite of (+)-JQ1(HY-13030). (+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC_50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy .

HY-W014883

1,12-Dodecanediamine 1,12-DD; 1,12-Diamino dodecane	Potassium Channel	Metabolic Disease
1,12-Dodecanediamine (1,12-DD) is a reversible *Maxi calcium-activated* potassium channel** blocker. 1,12-Dodecanediamine can reduce the single-channel current amplitude, mean channel open time, and channel open probability. 1,12-Dodecanediamine is promising for research of cell electrical signal transduction mechanism .

HY-14930A

Mirodenafil dihydrochloride SK-3530 dihydrochloride	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-14930

Mirodenafil SK3530	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-139664A

(R)-GSK-3685032	DNA Methyltransferase	Cancer
(R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC₅₀ of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .

HY-133233

Thioetheramide-PC 1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine	Endogenous Metabolite Phospholipase	Metabolic Disease
Thioetheramide-PC (1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine) is a structurally modified phospholipid that acts as a competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2). Thioetheramide-PC has an IC₅₀ value of 2 μM at a substrate concentration of 0.5 mM. In addition to binding to the catalytic site of sPLA2, Thioetheramide-PC also binds to the activation site of the enzyme. Thioetheramide-PC binds more tightly to the activation site than to the catalytic site. As a result of this dual interaction, at low concentrations, Thioetheramide-PC may activate phospholipase activity rather than inhibit it.

HY-19638AR

Cangrelor tetrasodium (Standard)	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
Cangrelor (tetrasodium) (Standard) is the analytical standard of Cangrelor (tetrasodium). This product is intended for research and analytical applications. Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist .

HY-153128

DOCK2-IN-1	DOCK	Inflammation/Immunology
DOCK2-IN-1 (compound 3), a CPYPP (HY-110100) analogue, is an inhibitor of DOCK2 as well (IC₅₀=19.1 μM). DOCK2-IN-1 binds to DOCK2 DHR-2 domain in a reversible manner to inhibits its catalytic activity. DOCK2-IN-1 blocks the activation of both chemokine receptor- and antigen receptor-mediated Rac in lymphocytes. DOCK2-IN-1 significantly suppresses chemotactic response and T cell activation .

HY-139664B

(S)-GSK-3685032	DNA Methyltransferase	Cancer
(S)-GSK-3685032 is the isomer of GSK-3685032 (HY-139664), and can be used as an experimental control. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC₅₀ of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .

HY-153508

ANO1-IN-4	Chloride Channel	Others
ANO1-IN-4 (Compound 10bm) is a reversible inhibitor for *calcium-activated* chloride channel transmembrane protein 16A (TMEM16A, also known as ANO1) with an IC₅₀** of 0.030 µM. ANO1-IN-4 exhibits good metabolic stability in rat liver microsomes. ANO1-IN-4 inhibits spontaneous contraction in mouse isolated ileum .

HY-134356

AICA-riboside, 5′-phosphate AICAR-5'-MP	Endogenous Metabolite	Others
AICA-riboside, 5′-phosphate is AICA riboside with a phosphate group. The functions of AICA riboside include: 1) conversion into AMP mimetic to selectively activate AMPK; 2) competition with adenosine for the uptake of nucleoside transporters, reversible blocking of adenosine reuptake, increasing extracellular adenosine concentration, and indirectly activating adenosine A1 receptors. AICA riboside is involved in metabolic regulation (promoting catabolism and inhibiting anabolism) and adenosine-dependent neuroprotection (inhibiting excitatory synaptic transmission). AICA riboside can be used in the study of metabolic diseases (such as diabetes and obesity) and neurological diseases (such as ischemia and epilepsy), and has central nervous system protective activity .

HY-100671

L002	Histone Acetyltransferase STAT	Cardiovascular Disease Inflammation/Immunology Cancer
L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC₅₀ of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment .

HY-14930R

Mirodenafil (Standard)	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-14930AR

Mirodenafil dihydrochloride (Standard)	Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis	Neurological Disease Inflammation/Immunology Endocrinology
Mirodenafil (dihydrochloride) (Standard) is the analytical standard of Mirodenafil (dihydrochloride). This product is intended for research and analytical applications. Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .

HY-132831

Selnoflast 1 Publications Verification Somalix; RO-7486967; IZD334	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .

HY-132831B

Selnoflast potassium Somalix potassium; RO-7486967 potassium; IZD334 potassium	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Selnoflast potassium (RO7486967 potassium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast potassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast potassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cardiovascular Disease Cancer
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible *protease-activated* receptor-1 (PAR1)** antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .

HY-164002

PF-303	Btk	Others
PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC₅₀=0.64 nM). The melamine portion of PF-303 forms a covalent bond with BTK's Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent BTK inhibitors. PF-303 can be used to model and study the effects of BTK inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation .

HY-132831A

Selnoflast calcium Somalix calcium; RO-7486967 calcium; IZD334 calcium	NOD-like Receptor (NLR) Interleukin Related	Neurological Disease Inflammation/Immunology
Selnoflast calcium (RO7486967 calcium), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast calcium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast calcium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease .

HY-103371

DCPIB 5+ Cited Publications	Chloride Channel Potassium Channel	Neurological Disease
DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC₅₀s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (I_Cl,swell), with an IC₅₀ of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .

Cat. No.	Product Name	Type

HY-W134005

Mg(Ⅱ)-EDTA disodium tetrahydrate Ethylenediaminetetraacetic acid magnesium disodium tetrahydrate	Chelators
Mg(Ⅱ)-EDTA disodium tetrahydrate is a reversible non-covalent activator of fructose diphosphatase (K_m=0.9 μM). Mg(Ⅱ)-EDTA disodium tetrahydrate synergistically activates fructose diphosphatase with free Mg ²⁺, promotes the hydrolysis of fructose-1,6-bisphosphate at pH≤8, and plays a role in enhancing the activity of key enzymes in gluconeogenesis .

Cat. No.	Product Name	Target	Research Area

HY-107146

PZ-128 P1pal-7	Protease Activated Receptor (PAR)	Cardiovascular Disease Cancer
PZ-128 (P1pal-7), a cell-penetrating lipopeptide pepducin, is a first-in-class, specific and reversible *protease-activated* receptor-1 (PAR1)** antagonist. PZ-128 targets the cytoplasmic surface of PAR1 and interrupts signaling to internally-located G (PAR1-G) proteins. PZ-128 has antiplatelet, anti-metastatic, anti-angiogenic and anticancer effects .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113221

Isovalerylcarnitine	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Proteasome Endogenous Metabolite
Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis .

HY-N0826

Corynoline 5 Publications Verification	Alkaloids Structural Classification other families Neurological Disease Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields Cancer	Cholinesterase (ChE) Keap1-Nrf2
Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC₅₀ of 30.6 μM . Corynoline exhibits anti-inflammatory activity by activating Nrf2 .

HY-134356

AICA-riboside, 5′-phosphate AICAR-5'-MP	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite
AICA-riboside, 5′-phosphate is AICA riboside with a phosphate group. The functions of AICA riboside include: 1) conversion into AMP mimetic to selectively activate AMPK; 2) competition with adenosine for the uptake of nucleoside transporters, reversible blocking of adenosine reuptake, increasing extracellular adenosine concentration, and indirectly activating adenosine A1 receptors. AICA riboside is involved in metabolic regulation (promoting catabolism and inhibiting anabolism) and adenosine-dependent neuroprotection (inhibiting excitatory synaptic transmission). AICA riboside can be used in the study of metabolic diseases (such as diabetes and obesity) and neurological diseases (such as ischemia and epilepsy), and has central nervous system protective activity .

HY-133178

Urolithin D 3,4,8,9-Tetrahydroxy urolithin	Structural Classification Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields Cancer	Ephrin Receptor PPAR AMPK
Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC₅₀ of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases .

HY-107301

Dehydrosoyasaponin I Soyasaponin Be; DHS-I	Structural Classification Polysaccharides Leguminosae Source classification Plants Saccharides Medicago sativa L.	Potassium Channel
Dehydrosoyasaponin I (Soyasaponin Be;DHS-I), a triterpene glycoside, is a potent and reversible *calcium-activated* potassium (maxi-K) channels** activator .

HY-113221R

Isovalerylcarnitine (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Proteasome Endogenous Metabolite
Isovalerylcarnitine (Standard) is the analytical standard of Isovalerylcarnitine. This product is intended for research and analytical applications. Isovalerylcarnitine is a product of the catabolism of L-leucine. Isovalerylcarnitine is also a selective and reversible calpain activator that induces apoptosis .

HY-N0826R

Corynoline (Standard)	Alkaloids Structural Classification other families Source classification Plants Isoquinoline Alkaloids	Reference Standards Cholinesterase (ChE) Keap1-Nrf2
Corynoline (Standard) is the analytical standard of Corynoline. This product is intended for research and analytical applications. Corynoline is a reversible and noncompetitive acetylcholinesterase (AChE) inhibitor with an IC₅₀ of 30.6 μM . Corynoline exhibits anti-inflammatory activity by activating Nrf2 .

HY-B1167A

Ajmaline hydrochloride Cardiorythmine hydrochloride; (+)-Ajmaline hydrochloride	Rauvolfia verticillata (Lour.) Baill. Apocynaceae Structural Classification Natural Products Source classification Plants	Others
Ajmaline hydrochloride is a Class Ia antiarrhythmic agent. It inhibits HERG potassium channels with IC50s of 1.0 μmol/l and 42.3 μmol/l in HEK cells and moth spider oocytes respectively. The inhibitory effect of Ajmaline hydrochloride is rapid, reversible, and positive frequency dependent. It acts primarily on the open state of the HERG channel and may also be combined with the inactivated state. The inhibitory effect of ajmaline hydrochloride is dependent on aromatic residues in the S6 domain, and the sensitivity is significantly reduced in the inactivation-deficient HERG S620T channel. It can also slightly affect the activation voltage of HERG channels. Ajmaline hydrochloride's inhibitory effect on HERG channels may contribute to both its potent antiarrhythmic effects and its potential proarrhythmic risk.

HY-133178R

Urolithin D (Standard) 3,4,8,9-Tetrahydroxy urolithin (Standard)	Structural Classification Microorganisms Source classification Phenols Polyphenols	Reference Standards Ephrin Receptor PPAR AMPK
Urolithin D (Standard) (3,4,8,9-Tetrahydroxy urolithin (Standard)) is the analytical standard of Urolithin D (HY-133178). This product is intended for research and analytical applications. Urolithin D (3,4,8,9-Tetrahydroxy urolithin) is a colonic metabolite of Ellagitannins and a competitive, reversible, and selective antagonist of the EphA receptor. Urolithin D inhibits EphA2-ephrin-A1 binding with an IC₅₀ of 0.9 μM. Urolithin D is also a potent antioxidant that scavenges free radicals and repairs oxidized DNA damage. Additionally, Urolithin D suppresses triglyceride accumulation and promotes fatty acid oxidation by activating the AMPK signaling pathway. Urolithin D can be used for research on tumors, metabolic, and inflammatory diseases .

Cat. No.	Product Name	Chemical Structure

HY-B0916S

Propoxur-d3

Propoxur-d₃ is the deuterated form of Propoxur (HY-B0916). Propoxur is a reversible, competitive, orally active AChE inhibitor that can cross the blood-brain barrier. Propoxur inhibits AChE activity to induce neurotoxicity, while promoting MMP-2 expression and enhancing tumor cell migration and invasion by inducing intracellular ROS generation and activating the ERK/Nrf2 signaling pathway. On the one hand, Propoxur inhibits AChE, leading to acetylcholine accumulation and causing neurological dysfunction; on the other hand, it promotes Nrf2 nuclear translocation through ROS-dependent ERK1/2 phosphorylation, and upregulates MMP-2 and other invasion-related proteins. Propoxur is also a carbamate insecticide used to combat turf, forestry, and household pests .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks